Review of Brazil's HIV/AIDS treatment programs shows importance of generic drugs, researchers say

"Brazil has been successful in its nearly 20-year effort to treat people living with" HIV/AIDS, and generic medicines have been "a large part of the solution," according to a recent Health Affairs review, UPI reports (UPI, 7/14).

The review examines Brazil's passing of "a law in the 1990s that guaranteed citizens free and universal access to drugs for HIV and AIDS treatment" as well as the country's production of generic HIV/AIDS medicines in public factories, AHN reports.  "The [Brazilian] government also prompted drug companies to lower their prices by threatening to make generic versions of [patented] HIV and AIDS drugs in the public factories," writes AHN (Goodhue, 7/14). 

"Brazil has proved it is possible to treat people with AIDS in developing countries," said lead author Amy Nunn, an assistant professor at Brown University, in a written statement. "[T]he country saved more than $1 billion as a result of bargaining with multinational pharmaceutical companies, resulting in significant changes in global AIDS policy," according to a Brown University/EurekAlert! release (7/14).

"Although Brazil's exact model might not be replicated elsewhere, it provides evidence that AIDS treatment is possible in a developing country," the authors write, adding, "Other countries, particularly middle-income countries, have learned much from Brazil’s experience as they now negotiate deep discounts with pharmaceutical companies, benefit from tiered pricing structures, issue compulsory licenses, rely increasingly on generics, work with blossoming civil-society movements, implement new health infrastructure, and provide millions of people with AIDS treatment" (Nunn et. al, Health Affairs, 7/09).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug